Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shionogi Partner BioAge Begins US PII Study for COVID-19 Drug
Shionogi said on March 23 that its US partner BioAge Labs has commenced a US PII study of its prostaglandin D2 DP1 receptor antagonist asapiprant (development code: S-555739/BGE-175) for the treatment of COVID-19 in patients aged 60 and above. Discovered…
To read the full story
Related Article
- BioAge Gets US/Europe Rights for Shionogi’s COVID-19 Treatment
January 27, 2021
BUSINESS
- Personal iPSC Service to Launch with Production Cost in the 10-Million-Yen Range
March 17, 2026
- Olumiant Gains Oral Suspension Formulation in Japan
March 17, 2026
- BMS Japan “On Track” to Double Sales by 2032 as Launch Wave Nears
March 17, 2026
- Hisamitsu Sets April 17 Shareholders Meeting to Approve Squeeze-Out
March 16, 2026
- AbbVie Japan Files Rinvoq for Vitiligo
March 16, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…